The Instituto de Biologia Experimental e Tecnológica - iBET is a private not for profit created in 1989 and specializing in biology research and drug discovery/ bioprocess development. At iBET, science and technology are exploited to accelerate translational application of competences from early stage discovery to final production and processes. As a Biotechnology Research Organization, iBET acts as an interface between academic and private institutions while also creating and organizing autonomous knowledge and expertise, and includes as shareholders 14 Portuguese companies, 10 academic and research institutions and foundations.
Hosting approximately 160 researchers and supported by an additional 400 through its partners ITQB and CEDOC/NOVA Medical School, iBET is fully compromised in a dynamic translational research programme, pursuing excellence in basic, developmental/preclinical and clinical research.
iBET is centered on 16 cutting-edge laboratories working in a broad range of fields that encompass multidisciplinary approaches ranging from basic, technological to clinical and translational research. Our expertise encompasses complex biopharmaceuticals and novel therapies including vaccines, recombinant proteins and viral vectors for gene therapy, the development of in-vitro models and methodologies for pre-clinical research and stem cells for cell therapy applications; protein stability and structure for assisted drug design, food and health, water, energy and nexus, and agro-forestry.
iBET has been involved in some of the most prestigious RD&I and technology transfer projects, with remarkable impact internationally at many scientific and technological domains, has participated as either coordinator or work-package leader in over 30 projects supported by the European Commission in the FP5, 6, 7 and H2020 initiatives and has established several prestigious international collaborations in Networks of Excellence.
Within iNOVA4Health, besides coordinating the the Unit, iBET brings in its recognized knowhow in the development of biopharmaceuticals, Advanced Therapy Medicine Product (ATMP) and Nutraceuticals, to the preclinical research activities critical for the program.